Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma.
about
Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission TomographyRandomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)Positron Emission Tomography (PET) in OncologyPlasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma.Therapy of Hodgkin's lymphoma in clinical practice: A retrospective long-term follow-up analysis.The role of fluorodeoxyglucose positron emission tomography-computerized tomography in resolving therapeutic dilemmas in pediatric Hodgkin lymphomaPrognostic Value of FDG-PET, Based on the Revised Response Criteria, in Patients with Malignant Lymphoma: A Comparison with CT/MRI Evaluations, Based on the International Working Group/Cotswolds Meeting Criteria.When should FDG-PET be used in the modern management of lymphoma?FDG PET/CT imaging as a biomarker in lymphoma.The role of FDG-PET in Hodgkin lymphomaThe role of 18F-FDG PET/CT in pediatric lymph-node acute lymphoblastic leukemia involvementThe prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma.Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients.Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010.Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival.
P2860
Q26801870-E2BC6A32-3D13-48BE-89AB-9E6548B5153CQ34645722-29CA3592-5F0E-44C3-8CB7-1D93DBD5C9FBQ34774840-0333AF9A-28CF-4E04-B4A9-11E4112A813CQ35794450-24951DFD-23FC-4EC0-BDDF-CA24EC161C76Q36135751-80A3C2F1-69EE-4A74-9AE2-082F0E37C969Q37058257-D21901D2-4A15-427B-807B-9D91AE8C6BDDQ37077176-456968E6-29BF-47D7-BEA8-B2996F1EEC82Q38153086-2E920C65-1BA3-4A5F-916B-162D8A0D8E33Q38312367-21952B1D-CAA9-4911-ADE6-FE014148B95FQ41691698-5F33F31D-6BAA-4B69-9C15-9BFE69746DACQ42041460-E9EA4175-DA2F-4B0E-B54D-4734E90C0473Q42317563-D6BEE3C0-9EEA-40BC-994E-504B8C8D996BQ49643393-F3822F72-BFA4-4DB4-B72F-DBBC15EAAE33Q51037023-11B5E1A8-E6BA-45BB-9F89-C12988B2CB39Q53164168-68B834BF-9FD3-4607-BBC0-B018D2DCEB16Q53235861-0F8B07EA-1D82-4202-B52F-889593C2DBFB
P2860
Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Positron emission tomography s ...... agement of Hodgkin's lymphoma.
@en
Positron emission tomography s ...... agement of Hodgkin's lymphoma.
@nl
type
label
Positron emission tomography s ...... agement of Hodgkin's lymphoma.
@en
Positron emission tomography s ...... agement of Hodgkin's lymphoma.
@nl
prefLabel
Positron emission tomography s ...... agement of Hodgkin's lymphoma.
@en
Positron emission tomography s ...... agement of Hodgkin's lymphoma.
@nl
P2860
P1433
P1476
Positron emission tomography s ...... agement of Hodgkin's lymphoma.
@en
P2093
Andrea Gallamini
P2860
P304
P356
10.3324/HAEMATOL.2010.024885
P577
2010-07-01T00:00:00Z